Amit Shah, MD
Internal Medicine · Indian Land, SCNPI 1740288323
Payments from drug & device makers
What this record shows
32 manufacturers reported payments, led by Chiesi USA, Inc. at 28.6% of the total. Reporting peaked in 2023 at $2,506 and has fallen 81.4% since, to $466 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $49.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$2K
- GSK$2K
- Merck$1K
- AbbVie$489
- Novo Nordisk$335
- Beigene USA, Inc.$251
- plus $1K from 26 others
Across 392 payments — averaging $3488.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$483K
- Regeneron$301K
- Novartis$148K
- GSK$123K
- AstraZeneca$120K
- Kowa Research Institute, Inc.$47K
- plus $146K from 13 others
What the payments were for
- Travel & lodging$3,37649%
- Food & beverage$3,56151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 5 | $1,984 |
| GSK | 16 | $1,535 |
| Merck | 12 | $1,132 |
| AbbVie(2 entities) | 23 | $489 |
| Novo Nordisk | 20 | $335 |
| Beigene USA, Inc. | 13 | $251 |
| Smith+Nephew | 1 | $142 |
| AstraZeneca | 4 | $123 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $103 |
| Amgen | 5 | $88 |
| Abbott | 4 | $83 |
| Lilly USA, LLC | 4 | $79 |
| Baxter Healthcare | 3 | $78 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Novartis | 3 | $47 |
| Beone Medicines USA, Inc. | 1 | $35 |
| Bayer | 2 | $31 |
| Boehringer Ingelheim | 1 | $31 |
| Mayne Pharma Commercial LLC | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Zimmer Biomet | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Exact Sciences | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Pfizer | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,937 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $41,321 |
| TrulicityDulaglutide | 21 | $29,341 |
| OzempicSemaglutide | 25 | $23,867 |
| VraylarCariprazine Hcl | 13 | $21,825 |
| JanuviaSitagliptin Phosphate | 16 | $13,822 |
| JardianceEmpagliflozin | 14 | $11,201 |
| VascepaIcosapent Ethyl | 11 | $5,830 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,569 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,289 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $4,059 |
| CreonLipase/Protease/Amylase | 13 | $2,627 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,267 |
| Levothyroxine Sodium | 234 | $1,840 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 11 | $1,767 |
| Gabapentin | 103 | $1,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $41,32143 claims |
| Lilly USA, LLCTrulicity | $79 | $29,34121 claims |
| AbbVieVraylar, Creon | $489 | $24,45226 claims |
| Novo NordiskOzempic | $335 | $23,86725 claims |
| MerckJanuvia | $1,132 | $13,82216 claims |
| Boehringer IngelheimJardiance | $31 | $11,20114 claims |
| AstraZenecaSymbicort | $123 | $4,28919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Indian Land
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
- Lisa DarbyGreenville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.